A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine As Second-line Treatment in Patients with Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Cemiplimab (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms SWITCH
- 31 Jan 2025 New trial record